Nine leukemia patients are cancer-free after being treated with genetically-altered versions of their own immune cells, giving strength to a promising new approach for treating the blood cancer.
The trial of 12 patients, two of them children, bolsters findings from 2011. Then, scientists from the University of Pennsylvania reported that two of the first three patients treated showed no traces of the malignancy after getting the therapy. The results were presented Sunday at the American Society of Hematology's annual meeting in Atlanta.
For Walter Keller, 59, who had failed every other treatment for his chronic lymphocytic leukemia diagnosed in 1996, the regimen meant he has been in remission since his treatment in April. Before the therapy, "I thought I had a year to live," he said.
"I feel better than I have in a long, long time," Mr. Keller, of Upland, Calif., said in a telephone interview. "I'm excited because I think this will help a lot of people."
The approach developed by Penn scientists has since been acquired by Novartis.
The scientists, led by Carl June, a professor of pathology and laboratory medicine at the Abramson Cancer Center at Penn and a study author, used genetic engineering to manipulate white blood cells extracted from the patients. The researchers reprogrammed the cells to specifically target the leukemia cells and reinjected them into the patients.
CLL is a slow-growing cancer that starts from white blood cells in the bone marrow and interferes with the production of healthy blood cells. The condition leads to complications such as immune deficiencies and swollen lymph nodes. The disease strikes about 16,000 adults each year and 4,600 die from it, according to the American Cancer Society.
The disease is treated with chemotherapy. Another approach is bone marrow transplant in which chemotherapy is first given to kill diseased cells then replaced with healthy ones from bone marrow extracted from the patient or a donor.
Mr. Keller underwent chemotherapy and then a stem cell transplant in 1998 and 1999. He was in remission for 51/2 years. He then underwent a different chemotherapy regimen and got a second stem cell transplant. The cancer came back again in 2010, and he had no options left. He was one of 10 adult patients treated so far.
"No patient who had complete remission has lost it," said Mr. Keller's doctor, David Porter, director of blood and marrow transplantation at Penn's Abramson Cancer Center. "It's unusual to have a treatment that can work to this magnitude and, until now, this duration."
Two of the original three patients treated have maintained their remissions over 2 years later. The scientists found signs of the designer blood cells still circulating in their bodies.
Two girls, ages 7 and 10, were also treated for a fast-growing blood cancer that affects children called acute lymphoblastic leukemia. Both had been treated and had then relapsed, said Stephan Grupp, director of Translational Research in the Center for Childhood Cancer Research at the Children's Hospital of Philadelphia. He presented research on their care at the hematology meeting.
One of the girls has been in complete remission in the 8 months since her treatment. The other had a remission of "a few months" before relapsing again, Dr. Grupp said. The younger girl had severe side-effects.
Previous studies have documented severe, flu-like illness in patients treated with their pumped-up immune cells. The 7-year-old's severe reaction helped explain what was happening, Dr. Grupp said. Her levels of an inflammatory protein called IL-6 were very high, 998 times her ordinary level. His group treated her with Roche's Actemra, approved for rheumatoid arthritis, which targets the protein. Because her levels of another inflammatory protein called TNF were high, she was also treated with Amgen and Pfizer's Enbrel.
"The next morning, she was dramatically better," Dr. Grupp said.
Her reaction suggests that the illness caused by the treatment is the result of an overactive immune system. Previously it wasn't clear what had caused the reactions, since tumors also release poisons when they're broken up to be cleared from the system.
Novartis funded a $20 million research center at Penn, as well as paying an undisclosed amount of money for rights to the therapy in August. The therapy will be called CTL019 by the drugmaker.
Sunday's research was funded by the Leukemia & Lymphoma Society, the Alliance for Cancer Gene Therapy and the National Institutes of Health.health - science